Open Orphan Plc (CRO) AI Stock Analysis

10 Followers

Open Orphan Plc

(Frankfurt:CRO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Record order bookThe record order book provides revenue visibility beyond the immediate reporting period and into 2027 and 2028. Combined with a 45% increase in proposals and 26% growth in proposal value, it supports the prospect of renewed demand and a stronger medium-term workload.

Negative Factors

Sharp profitability deteriorationThe latest annual results show that the earnings profile has become materially weaker and more volatile. Negative gross profit and a sizable net loss reduce internal funding capacity, make recovery dependent on execution, and weaken the financial cushion available for continued investment.

Open Orphan Plc (CRO) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 34.76M
Dividend Yield: 4.54%
Average Volume (3M): ―
Price to Earnings (P/E): -2.8
Beta (1Y): 0.31
Revenue Growth: -26.76%
EPS Growth: -321.51%
Country: Germany
Employees: 376
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Open Orphan Plc Business Overview & Revenue Model

Company Description

hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical dev...

Open Orphan Plc Earnings Call Summary

Earnings Call Date:Sep 15, 2026(Q2-2026)|% Change Since:-22.39%|Next Earnings Date:Apr 14, 2027

Earnings Call SentimentPositive

The call was positive overall despite weak first-half financial results, a GBP 47 million full-year revenue outlook below consensus, contract delays and an expected full-year EBITDA loss. Management emphasized record order-book levels, a recovering human challenge trial pipeline, 110% laboratory revenue growth, diversification into new therapeutic areas and an immediately accretive CRS Berlin acquisition. The deferred contracts were explicitly described as delayed rather than canceled, and management expressed confidence in significant growth and positive EBITDA in 2027.

Positive Updates

Record Order Book and Stronger Sales Pipeline

New proposals increased 45% year on year, while the value of proposals increased 26%. The underlying order book reached GBP 65 million at the end of June 2026 and GBP 72 million including CRS Berlin, the highest level in the company's history. Management said the order book provides excellent visibility for the remainder of 2026 and into 2027 and 2028.

Negative Updates

First-Half Revenue Decline

First-half 2026 revenue was GBP 16.3 million, down from GBP 24 million in the first half of 2025. Management attributed the difference primarily to lower human challenge trial revenue, following the high level of cancellations in 2025 and the deferral of expected 2026 work.

Company Guidance

For full year 2026, hVIVO is guiding to around GBP 47 million of revenue, including GBP 31 million in H2 2026, which is almost double H1 2026 revenue of GBP 16.3 million; it expects to be EBITDA positive in H2 and to reduce the H1 EBITDA loss of GBP 4.5 million to a low single-digit loss for the full year, defined as anywhere between GBP 2 million and GBP 3 million, with cash expected to be about down to about GBP 8 million or GBP 9 million at the end of December. For 2027, management is forecasting significant year-on-year growth and positive EBITDA, with brokers consensus around mid to high 50s, while CRS Berlin is expected to contribute GBP 3 million of revenue and GBP 0.5 million of EBITDA in the four months owned, with an expected 10%-12% margin going forward and an aspirational 15% to 20%.

Open Orphan Plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CRO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:IXI	55Neutral	GBP 27.92M	-6.50	-16.18%	―	13.04%	15.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:APTA	46Neutral	GBP 12.66M	-12.17	-46.61%	―	28.35%	57.14%
GB:AVCT	40Underperform	GBP 287.20M	-6.47	-1293.07%	―	―	―
GB:FAB	40Underperform	GBP 5.32M	-4.29	-97.87%	―	7.38%	44.13%
GB:OBD	40Underperform	GBP 15.46M	-0.29	-451.74%	―	33.37%	86.41%

* Healthcare Sector Average

Performance Comparison

DE:CRO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CRO	Open Orphan Plc	0.05	-0.01	-17.46%
GB:AVCT	Avacta Group plc	59.00	-22.00	-27.16%
GB:IXI	IXICO plc	12.75	1.50	13.33%
GB:OBD	Oxford BioDynamics	0.12	-0.17	-58.93%
GB:FAB	Fusion Antibodies Plc	4.25	-8.00	-65.31%
GB:APTA	Aptamer Group Plc	0.36	-0.57	-60.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Open Orphan Plc AI Stock Analysis